# What the TRIUMPH trial is designed to measure about physical function

- Article ID: research-371
- Product: Tesamorelin (tesamorelin-676, tesamorelin-538, tesamorelin-675)
- Canonical page: https://heritagebiolabs.com/research-library/articles/371-what-the-triumph-trial-is-designed-to-measure-about-physical-function
- Product collection: https://heritagebiolabs.com/research-library/products/tesamorelin
- Product page: https://heritagebiolabs.com/product/tesamorelin-676
- Product page: https://heritagebiolabs.com/product/tesamorelin-538
- Product page: https://heritagebiolabs.com/product/tesamorelin-675
- Reading focus: Methods & identity (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Short chains of amino acids connected by peptide bonds can act as signals. Tesamorelin is a 44-residue growth hormone–releasing hormone analogue with a chemical modification at its starting end. It can stimulate the pituitary to release growth hormone. A trial protocol published in July 2026 asks whether adding tesamorelin to an exercise program improves physical function in adults with HIV. [1, 2]

The protocol describes a randomized, blinded comparison of tesamorelin and placebo alongside the same exercise program. That design is intended to help distinguish changes associated with adding the drug from changes that might occur in both groups because of exercise or other parts of the study. The primary outcome is the change in how long participants take to complete a series of repeated chair stands. The test measures a movement that draws on leg strength, balance and coordination. [1]

The researchers also plan to collect other measurements, including muscle and fat images and laboratory measures of muscle tissue. These describe different aspects of the response. An image can show a difference in muscle size or composition without establishing that a person moves more easily. A timed task can show a functional change while leaving open which tissue or biological pathway contributed to it. Measuring both types of outcome can help the investigators compare the patterns. [1]

A protocol sets out a study question, comparison groups and planned measurements before results are reported. The authors explain what effect they are trying to detect and how they plan to analyze randomized participants. Those details are useful for judging the completed study when results are available. The protocol does not contain completed outcome data or show that either group improved. [1]

The approved U.S. indication for Egrifta WR is reduction of excess abdominal fat in adults with HIV-associated lipodystrophy. The TRIUMPH research question concerns physical function in an exercise setting. It is a separate investigated use, with a primary measurement that directly tests performance on a task rather than assuming that a change in body composition will improve movement. [1, 2]

## Sources

1. Erlandson KM et al. Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol. BMJ Open (publication 2026-07-08). <https://pubmed.ncbi.nlm.nih.gov/42419889/>
2. Theratechnologies. EGRIFTA WR- tesamorelin kit. U.S. prescribing information on DailyMed (updated 2026-07-29). <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 075 - Tesamorelin.docx; article 371; content SHA-256 7852c0408e04df468807477732e86dc46049dbc65090885490c9706294697d65.
